HM15136

Pipeline

Status by Indication[3][1]

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Overweight1 trial

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

Completed·Hanmi Pharmaceutical Company Limited·Phase 1·NCT04167553·52 enrolled

Tics1 trial

A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects

Completed·Hanmi Pharmaceutical Company Limited·Phase 1·NCT04032782·40 enrolled

Congenital Hyperinsulinism1 trial

A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

Active, not recruiting·Hanmi Pharmaceutical Company Limited·Phase 2·NCT04732416·17 enrolled

Details

Drug Info

Related News